Dear Doctor Letter (Rote-Hand-Brief) on medicinal products containing pioglitazone (Actos®, Competact®, Tandemact®): New contraindications and warnings due to a slightly increased risk of bladder cancer
2011.08.01
Active substance: pioglitazone
The pharmaceutical entrepreneur is sending out a Rote-Hand-Brief giving information on new contraindications and warnings due to a slightly increased risk of bladder cancer.
The BfArM already published information on this risk on 10 June 2011.
The BfArM continues its recommendation not to administer medicinal products containing pioglitazone to any new patients.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN